John Stendahl, MD, PhD
Assistant Professor of Medicine (Cardiovascular Medicine)Cards
About
Research
Publications
2025
Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA–Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy
Saberi S, Kramer C, Oręziak A, Masri A, Barriales-Villa R, Abraham T, Lakdawala N, Wang A, Choudhury L, Rader F, Havakuk O, Stendahl J, Cardim N, Seidler T, Sherrid M, Hegde S, Kwong R, Jerosch-Herold M, Balaratnam G, Kurio G, Fox S, Olivotto I, Owens A. Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA–Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy. Circulation 2025, 152: 905-908. PMID: 40982583, DOI: 10.1161/circulationaha.124.071188.Peer-Reviewed Original ResearchHealth Care Resource Use and Economic Burden in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation.
Stendahl J, Sen S, Butzner M, Papademetriou E, Potluri R, Liu X, Jacoby D, Freeman J. Health Care Resource Use and Economic Burden in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation. Journal Of The American Heart Association 2025, 14: e038755. PMID: 40847492, DOI: 10.1161/jaha.124.038755.Peer-Reviewed Original ResearchConceptsSymptomatic obstructive hypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathyHealth care resource useCare resource useHealth care costsAtrial fibrillationTotal health care costsIncident AFCare costsHypertrophic cardiomyopathyRetrospective analysisSeptal reduction therapyGreater health care costsRetrospective analysis of claims dataDiagnosis of AFImpact of AFResource useAnalysis of claims dataAdult patientsReduction therapyPatient managementUrgent carePatientsClaims dataCardiomyopathyCurrent management of hypertrophic cardiomyopathy
Sikand N, Stendahl J, Sen S, Lampert R, Day S. Current management of hypertrophic cardiomyopathy. The BMJ 2025, 389: e077274. PMID: 40425241, DOI: 10.1136/bmj-2023-077274.Peer-Reviewed Original ResearchConceptsOutflow tract gradientObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyAtrial fibrillationLeft ventricular outflow tract gradientNon-obstructive hypertrophic cardiomyopathyManagement of hypertrophic cardiomyopathyRisk of sudden deathCardiac sarcomere genesImplantable cardioverter-defibrillator implantationSeptal reduction therapyNon-obstructive diseaseSymptomatic atrial fibrillationCardiac myosin inhibitorLeft ventricular hypertrophySurgical treatment optionsCardioverter-defibrillator implantationAdvanced heart failureStructural heart conditionsArrhythmic riskCardiac transplantationImprove patient outcomesRhythm controlMedical therapyVentricular hypertrophyDIFFERENCES IN PATIENT CHARACTERISTICS AND BURDEN OF DISEASE IN ADULTS WITH MYBPC3-ASSOCIATED HCM
Wang W, Varfaj B, Robertson L, Harrison W, Haroldson J, Tingley W, Lakdawala N, Owens A, Saberi S, Lin K, Stendahl J, Parikh V, Ingles J, Ashley E, Ware J, Michels M, Lampert R, Abrams D, Rossano J, Russell M, Ryan T, Olivotto I, Day S, Ho C, Helms A. DIFFERENCES IN PATIENT CHARACTERISTICS AND BURDEN OF DISEASE IN ADULTS WITH MYBPC3-ASSOCIATED HCM. Journal Of The American College Of Cardiology 2025, 85: 1513. DOI: 10.1016/s0735-1097(25)01997-7.Peer-Reviewed Original ResearchPO-07-051 RISK STRATIFICATION IN MIDDLE-AGED AND OLDER ADULTS WITH HYPERTROPHIC CARDIOMYOPATHY: INSIGHTS FROM THE SARCOMERIC HUMAN CARDIOMYOPATHY REGISTRY (SHARE)
Alaiwi S, Lampert R, Day S, Ho C, Helms A, Olivotto I, Ashley E, Ingles J, Gray B, Lakdawala N, Owens A, Saberi S, Parikh V, Stendahl J. PO-07-051 RISK STRATIFICATION IN MIDDLE-AGED AND OLDER ADULTS WITH HYPERTROPHIC CARDIOMYOPATHY: INSIGHTS FROM THE SARCOMERIC HUMAN CARDIOMYOPATHY REGISTRY (SHARE). Heart Rhythm 2025, 22: s755. DOI: 10.1016/j.hrthm.2025.03.1811.Peer-Reviewed Original ResearchSex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy
Butters A, Arnott C, Sweeting J, Claggett B, Cuomo A, Abrams D, Ashley E, Day S, Helms A, Lampert R, Lin K, Michels M, Miller E, Olivotto I, Owens A, Parikh V, Pereira A, Rossano J, Ryan T, Saberi S, Stendahl J, Ware J, Atherton J, Semsarian C, Lakdawala N, Ho C, Ingles J. Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy. Circulation Genomic And Precision Medicine 2025, 18: e004641. PMID: 39851041, DOI: 10.1161/circgen.124.004641.Peer-Reviewed Original ResearchConceptsRisk of heart failureSex-specific hazard ratiosHazard ratioHypertrophic cardiomyopathyAdverse outcomesHeart failureSex interaction termsFactors associated with adverse outcomesRisk of atrial fibrillationVentricular arrhythmiasCox proportional hazards modelsSarcomeric Human Cardiomyopathy RegistryManagement of hypertrophic cardiomyopathyProportional hazards modelInvestigate sex-related differencesSex differencesHeart failure riskRisk scoreHigher heart failureModerate riskHazards modelRisk factorsCardiomyopathy RegistryDeath riskImprove outcomes
2024
Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy
Meisner J, Renberg A, Smith E, Tsan Y, Elder B, Bullard A, Merritt O, Zheng S, Lakdawala N, Owens A, Ryan T, Miller E, Rossano J, Lin K, Claggett B, Ashley E, Michels M, Lampert R, Stendahl J, Abrams D, Semsarian C, Parikh V, Wheeler M, Ingles J, Olivotto I, Day S, Saberi S, Russell M, Previs M, Ho C, Ware J, Helms A. Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy. Circulation 2024, 151: 783-798. PMID: 39633578, PMCID: PMC11913586, DOI: 10.1161/circulationaha.124.069398.Peer-Reviewed Original ResearchPathogenic sarcomeric variantsOvert hypertrophic cardiomyopathySarcomere variantsHypertrophic cardiomyopathyGeneral populationSarcomeric genesCardiac magnetic resonance imaging analysisSarcomeric Human Cardiomyopathy RegistryInduced pluripotent stem cell-derived cardiomyocytesPluripotent stem cell-derived cardiomyocytesStem cell-derived cardiomyocytesAssociated with disease severityDisease severityCardiac magnetic resonance imaging dataCell-derived cardiomyocytesMagnetic Resonance Imaging AnalysisMild hypertrophic cardiomyopathyIncreased disease severityCardiomyopathy RegistryDisease riskClinical outcomesAdverse eventsSignificant additive effectsEffect sizePolygenic contributionThe Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic Cardiomyopathy
Ahluwalia M, Liu J, Olivotto I, Parikh V, Ashley E, Michels M, Ingles J, Lampert R, Stendahl J, Colan S, Abrams D, Pereira A, Rossano J, Ryan T, Owens A, Ware J, Saberi S, Helms A, Day S, Claggett B, Ho C, Lakdawala N. The Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Heart Failure 2024, 13: 332-343. PMID: 39520446, DOI: 10.1016/j.jchf.2024.09.008.Peer-Reviewed Original ResearchObstructive hypertrophic cardiomyopathyClass I patientsFunctional class II patientsNYHA functional class IClass II patientsFunctional class II patientsII patientsHypertrophic cardiomyopathyFollow-upLeft ventricular outflow tract obstructionVentricular outflow tract obstructionNYHA functional class IILeft ventricular ejection fractionRates of clinical outcomesClass INatural historyRestricted cubic spline modelsSeptal reduction therapyOutflow tract obstructionFunctional class IIVentricular ejection fractionComposite event rateCubic spline modelsCox proportional hazardsCoordinate-Independent 3-D Ultrasound Principal Stretch and Direction Imaging
Jeng G, Chen P, Hsieh M, Liu Z, Langdon J, Ahn S, Staib L, Stendahl J, Thorn S, Sinusas A, Duncan J, O'Donnell M. Coordinate-Independent 3-D Ultrasound Principal Stretch and Direction Imaging. IEEE Transactions On Biomedical Engineering 2024, 71: 3312-3323. PMID: 38941195, PMCID: PMC11637688, DOI: 10.1109/tbme.2024.3420220.Peer-Reviewed Original ResearchPrincipal stretchesAxial displacement componentsSpeckle tracking methodSpeckle tracking approachTracking methodRobust filterDisplacement componentsTissue incompressibilityDisplacement estimationStrain componentsDisplacement gradientsStrain informationLocalized diseased regionStrain imagingLagrangian strainLeast-squares methodTracking approachTracking frameworkCoordinate systemCardiac coordinate systemProbe orientationFilterHigher spatial resolutionCardiac datasetsEnhanced accuracyLong-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry
Maurizi N, Antiochos P, Owens A, Lakdwala N, Saberi S, Russell M, Fumagalli C, Skalidis I, Lin K, Nathan A, De Feria Alsina A, Reza N, Stendahl J, Abrams D, Semsarian C, Clagget B, Lampert R, Wheeler M, Parikh V, Ashley E, Michels M, Rossano J, Ryan T, Ingles J, Ware J, Ho C, Helms A, Day S, Olivotto I. Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry. Circulation 2024, 150: 1377-1390. PMID: 39355918, PMCID: PMC11493522, DOI: 10.1161/circulationaha.124.069378.Peer-Reviewed Original ResearchSeptal reduction therapyHCM-related deathOutflow tract obstructionObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyHeart failureComposite outcomeMaximal left ventricular outflow tract gradientRecurrent left ventricular outflow tract obstructionRelief of outflow tract obstructionLeft ventricular outflow tract gradientLeft ventricular outflow tract obstructionReduction therapyVentricular outflow tract obstructionDe novo atrial fibrillationPredictor of adverse outcomesOccurrence of heart failureAlcohol septal ablationOutflow tract gradientEvent-free survivalLong-term disease courseHypertrophic cardiomyopathy centersLong-term reliefCox proportional hazards modelsLong-term outcomes
Academic Achievements & Community Involvement
Clinical Care
Overview
John Stendahl, MD, PhD, specializes in cardiovascular imaging and the diagnosis and management of inherited and infiltrative cardiomyopathies. He provides a patient-centered approach to care that is based on the latest scientific findings and diagnostics, and often involves genetic analysis and various types of advanced cardiac imaging.
Dr. Stendahl treats a variety of complex conditions, including hypertrophic, dilated, and arrhythmogenic cardiomyopathies, as well as cardiac amyloid. He performs and interprets various cardiovascular imaging studies, including cardiovascular SPECT, PET, and CT scans. His work includes stress testing and coronary CT for the diagnosis and treatment of coronary artery disease, as well as the latest molecular imaging techniques to evaluate various forms of cardiomyopathy.
In addition to caring for patients, Dr. Stendahl performs clinical and translational research pertaining to hypertrophic cardiomyopathy, heart failure, cardiac transplantation, cardiac devices, and cardiovascular imaging. This includes clinical trials of the latest medications to treat cardiomyopathies, as well as translational work focused on development and discovery.
Clinical Specialties
Cardiovascular Medicine
Fact Sheets
Hypertrophic Cardiomyopathy
Learn More on Yale MedicineCT Scan for Coronary Artery Disease
Learn More on Yale MedicineChronic Total Occlusion (CTO)
Learn More on Yale MedicinePulmonary Edema
Learn More on Yale Medicine
Board Certifications
Nuclear Cardiology
- Certification Organization
- Certification Board of Nuclear Cardiology
- Original Certification Date
- 2020
Yale Medicine News
News
News
- January 16, 2024
Yale's Cardiac Imaging Center Revolutionizes Translational Research
- May 17, 2023
Feher selected for ASNC leadership development program
- April 24, 2023Source: HealthCentral
Top HCM Fears and How to Conquer Them
- February 01, 2023
2023 American College of Cardiology late-breaking clinical trials and abstracts from Yale
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.